Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 11,325 matching trials from the live ClinicalTrials.gov search.
Filters: Cleveland, Ohio Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effectiveness of an Eight Week Online Mediterranean Based Diet

NCT01532258
View directory record Official record
Conditions
Obesity
Interventions
Go! Foods for You without Weekly MA Support., Go! Foods for You with Weekly MA Support.
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 2 Interventional Results available

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02807558
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Tamibarotene, Azacitidine, Daratumumab
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
Hartford, Connecticut • Miami, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 2, 2026, 10:08 AM EST
Terminated Not applicable Interventional Results available

Vaginal Hysterectomy vs Supracervical Hysterectomy at the Time of Sacrocolpopexy

NCT04797585
View directory record Official record
Conditions
Vaginal Hysterectomy, Laparoscopic Supracervical Hysterectomy
Interventions
Laparoscopic supracervical hysterectomy, Vaginal hysterectomy
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 2, 2026, 10:08 AM EST
Completed Not applicable Interventional Results available

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation

NCT00583778
View directory record Official record
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Nov 2, 2026, 10:08 AM EST
Terminated Not applicable Interventional

Anesthetic Effects in Mitochondrial Disease

NCT01001585
View directory record Official record
Conditions
Mitochondrial Disease
Interventions
sevoflurane
Drug
Lead sponsor
d sessler
Other
Eligibility
12 Months to 16 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 4 Interventional

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

NCT00211198
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
ONTAK (denileukin difitox, DAB389IL-2)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
9
States / cities
Duarte, California • New Haven, Connecticut • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 3 Interventional Results available

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

NCT00123487
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 2 Interventional Results available

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

NCT02161406
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 2, 2026, 10:08 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Novel Brain Stimulation Therapies in Stroke Guided Expressions of Plasticity

NCT03020433
View directory record Official record
Conditions
Stroke, Cerebrovascular Disorders, Nervous System Diseases, Brain Diseases, Cardiovascular Diseases, Vascular Diseases, Central Nervous System Diseases
Interventions
rTMS Contralesional M1, rTMS Contralesional PMC, rTMS Ipsilesional PMC, rTMS sham at Ipsilesional M1
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Nov 2, 2026, 10:08 AM EST
Completed No phase listed Observational

Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

NCT00900133
View directory record Official record
Conditions
Breast Cancer
Interventions
immunoenzyme technique, laboratory biomarker analysis
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Nov 2, 2026, 10:08 AM EST
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1226
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

NCT00195715
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
63
States / cities
Huntsville, Alabama • Jacksonville, Alabama • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Nov 2, 2026, 10:08 AM EST
Active, not recruiting Not applicable Interventional

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

NCT06137807
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Disease
Interventions
TricValve® Transcatheter Bicaval Valve System
Device
Lead sponsor
P+F Products + Features USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 2, 2026, 10:08 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine

NCT03731221
View directory record Official record
Conditions
Video Assisted Thoracic Surgery
Interventions
Bupi HCI and lipo bupi, Bupi HCI
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Nov 2, 2026, 10:08 AM EST
Completed Not applicable Interventional Results available

A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients

NCT04065048
View directory record Official record
Conditions
Crohn Disease
Interventions
Soy based diet, Non-soy based diet
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 2, 2026, 10:08 AM EST
Recruiting Not applicable Interventional

Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device

NCT07456865
View directory record Official record
Conditions
Urge Urinary Incontinence
Interventions
Altaviva™ system
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Homewood, Alabama • Glendale, Arizona • Idaho Falls, Idaho + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 1Phase 2 Interventional

Safety and Tolerability of Perampanel in Cervical Dystonia

NCT02131467
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Perampanel
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Nov 2, 2026, 10:08 AM EST
Completed Phase 3 Interventional Results available

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

NCT04542499
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Nov 2, 2026, 10:08 AM EST
Recruiting Not applicable Interventional

Left vs Left Randomized Clinical Trial

NCT05650658
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
Interventions
His/LBBP, BiVP
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
57
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Nov 2, 2026, 10:08 AM EST
Terminated Phase 3 Interventional

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

NCT05263999
View directory record Official record
Conditions
Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Interventions
Itolizumab, EQ001 Placebo
Biological · Drug
Lead sponsor
Equillium
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Nov 2, 2026, 10:08 AM EST
Terminated No phase listed Observational

The Use of CT to Identify Damaged Heart Muscle in Patients Undergoing Ventricular Tachycardia Ablation.

NCT00583284
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Nov 2, 2026, 10:08 AM EST
Terminated No phase listed Observational

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

NCT01586858
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Observational
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Nov 2, 2026, 10:08 AM EST
Suspended Phase 2 Interventional

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478
View directory record Official record
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 2, 2026, 10:08 AM EST